StockData
Heron Therapeutics, Inc. logo

Heron Therapeutics, Inc. (HRTX) stock

HRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$0.27−0.01 (-3.26%)

Close on Nov 18, 2026Market cap $51.83MP/E –Yield –

Heron Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Heron Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$10.86M, down 981.8% year over year. For fiscal 2025 it was -$2.54M. The highest annual figure on record is -$2.54M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$2.54M–
FY2024Dec 31, 2024-$11.53M–
FY2023Dec 31, 2023-$110.62M–
FY2022Dec 31, 2022-$174.66M–
FY2021Dec 31, 2021-$217.83M–
FY2020Dec 31, 2020-$228.16M–
FY2019Dec 31, 2019-$210.69M–
FY2018Dec 31, 2018-$183.94M–
FY2017Dec 31, 2017-$194.56M–
FY2016Dec 31, 2016-$170.92M–
FY2015Dec 31, 2015-$96.93M–
FY2014Dec 31, 2014-$74.56M–
FY2013Dec 31, 2013-$54.46M–
FY2012Dec 31, 2012-$23.83M–
FY2011Dec 31, 2011-$11.06M–
FY2010Dec 31, 2010-$9.93M–
FY2009Dec 31, 2009-$10.24M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$2.04M–
Q1 FY2026Mar 31, 2026-$4.77M-251.1%
Q4 FY2025Dec 31, 2025$38.00K-99.1%
Q3 FY2025Sep 30, 2025-$4.09M–
Q2 FY2025Jun 30, 2025-$1.64M–
Q1 FY2025Mar 31, 2025$3.15M–
Q4 FY2024Dec 31, 2024$4.17M–
Q3 FY2024Sep 30, 2024-$4.46M–
Q2 FY2024Jun 30, 2024-$6.45M–
Q1 FY2024Mar 31, 2024-$4.80M–
Q4 FY2023Dec 31, 2023-$10.22M–
Q3 FY2023Sep 30, 2023-$24.93M–
Q2 FY2023Jun 30, 2023-$42.40M–
Q1 FY2023Mar 31, 2023-$33.06M–
Q4 FY2022Dec 31, 2022-$20.36M–
Q3 FY2022Sep 30, 2022-$41.88M–
Q2 FY2022Jun 30, 2022-$49.50M–
Q1 FY2022Mar 31, 2022-$62.92M–
Q4 FY2021Dec 31, 2021-$53.54M–
Q3 FY2021Sep 30, 2021-$51.71M–
Q2 FY2021Jun 30, 2021-$60.47M–
Q1 FY2021Mar 31, 2021-$52.11M–
Q4 FY2020Dec 31, 2020-$61.30M–
Q3 FY2020Sep 30, 2020-$58.38M–
Q2 FY2020Jun 30, 2020-$55.75M–
Q1 FY2020Mar 31, 2020-$52.73M–
Q4 FY2019Dec 31, 2019-$59.36M–
Q3 FY2019Sep 30, 2019-$34.85M–
Q2 FY2019Jun 30, 2019-$51.78M–
Q1 FY2019Mar 31, 2019-$64.70M–
Q4 FY2018Dec 31, 2018-$51.31M–
Q3 FY2018Sep 30, 2018-$41.78M–
Q2 FY2018Jun 30, 2018-$38.85M–
Q1 FY2018Mar 31, 2018-$51.99M–
Q4 FY2017Dec 31, 2017-$61.89M–
Q3 FY2017Sep 30, 2017-$41.31M–
Q2 FY2017Jun 30, 2017-$42.06M–
Q1 FY2017Mar 31, 2017-$49.30M–
Q4 FY2016Dec 31, 2016-$46.80M–
Q3 FY2016Sep 30, 2016-$47.73M–

More Heron Therapeutics figures

See a number that looks wrong?